吉西他滨联合卡铂治疗复发卵巢上皮癌的临床观察

目的观察吉西他滨联合卡铂治疗复发卵巢上皮癌的临床疗效和毒副反应。方法58例复发卵巢上皮癌患者用吉西他滨1000mg／m^2 ＋生理盐水100ml，静脉滴注30min，第1天和第8天；卡铂剂量AUC5，第1天静脉滴注；21天为一个周期。观察治疗后近期总有效率、中住无进展生存期及不良反应。结果58例患者中，完全缓解13例，部分缓解28例，稳定12例，进展5例，治疗总有效率70．7％。患者中住无进展生存期5．8个月（2～11个月）。化疗主要毒副反应为骨髓抑制和胃肠道反应，未出现因化疗毒性而死亡的病例。结论吉西他滨联合卡铂是治疗复发性卵巢上皮癌的有效方法，化疗不良反应可耐受，安全性高，具有临床应用价值。

Treatment of recurrent epithelial ovarian cancer with gemcitabine combined with carboplatin

ObjectiveTo observe the efficacy of gemcitabine combined with carboplatin on treatment of recurrent epithelial ovarian cancer.MethodsGemcitabine 1000mg/m2 was intravenously administered to 58 patients with recurrent epithelial ovarian cancer for 30 minute on days 1 and 8.Carboplatin AUC 5 was intravenously administered on day 1.Cycles were repeated every 21 days.The overall response rate,the mean progression-free survival and side effects were observed and analyzed.ResultsThe overall response rate was 70.7% for 58 patients.Complete response was achieved in 13,partial response in 28,stable disease in 12 and progression disease in 5.The mean progression-free survival was 5.8 months(2 to 11 months).The main adverse effects were marrow suppression including of leucopenia and thrombocytopenia,no patients dead for toxic reactions of chemotherapy.ConclusionGemcitabine combined with carboplatin is effective and secure on patients with recurrent epithelial ovarian cancer.The side effects are tolerable.